Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex

European Journal of Pharmacology

Volumn 461, Issue 2-3, 2003, Pages 93-98

  Okamura, Naoe ^a   Hashimoto, Kenji ^a   Kanahara, Nobuhisa ^a   Shimizu, Eiji ^a   Kumakiri, Chikara ^a   Komatsu, Naoya ^a   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

(Rat); Clozapine; Dizocilpine (MK 801); Glutamate; Schizophrenia; Zotepine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CLOZAPINE; DIZOCILPINE; HEAT SHOCK PROTEIN 70; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ZOTEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL VACUOLE; CONTROLLED STUDY; DISEASE MARKER; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNOHISTOCHEMISTRY; NERVE CELL; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCHIZOPHRENIA;

EID: 0037436057     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01303-7     Document Type: Article

References (33)

1. Brown I.R. The stress response. Neuropathol. Appl. Neurobiol. 21:1995;473-475.
2. Calabrese J.R., Kimmel S.E., Woyshville M.J., Rapport D.J., Faust C.J., Thompson P.A., Meltzer H.Y. Clozapine for treatment-refractory mania. Am. J. Psychiatry. 153:1996;759-764.
3. Cooper S.J., Tweed J., Raniwalla J., Butler A., Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr. Scand. 101:2000;218-225.
4. Dieterle D.M., Ackenheil M., Muller-Spahn F., Kapfhammer H.P. Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry. 20:1987;52-57.
5. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry. 7:2002;32-43.
6. Fleischhacker W.W. Clozapine: a comparison with other novel antipsychotics. J. Clin. Psychiatry. 60(Suppl. 12):1999;30-34.
7. Fujimura M., Hashimoto K., Yamagami K. Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine. Eur. J. Pharmacol. 398:2000;1-10.
8. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 24:2001;527-533.
9. Gattaz W.F., Schummer B., Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J. Neural Transm., Gen. Sect. 96:1994;227-232.
10. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377.
11. Harada T., Otsuki S. Antimanic effect of zotepine. Clin. Ther. 8:1986;406-414.
12. Hashimoto K., Iyo M. Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs. Nihon Shinkei Seishin Yakurigaku Zasshi. 22:2002;3-13.
13. Hashimoto K., Tomitaka S., Narita N., Minabe Y., Iyo M., Fukui S. Induction of heat shock protein HSP-70 in rat retrosplenial cortex of rat brain by dizocilpine and phencyclidine: lack of protective effects of sigma receptor ligands. Addict. Biol. 1:1996;61-70.
14. Hashimoto K., Tomitaka S., Bi Y., Narita N., Minabe Y., Iyo M. Rolipram, a selective phosphodiesterase type-IV inhibitor, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by the NMDA receptor antagonist dizocilpine. Eur. J. Neurosci. 9:1997;1891-1901.
15. Hashimoto K., Fujimura M., Yamagami K. Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment. Life Sci. 66:2000;1071-1078.
16. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
17. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
18. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry. 7:1999;125-143.
19. Meyer Lindenberg A., Gruppe H., Bauer U., Lis S., Krieger S., Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry. 30:1997;35-42.
20. Needham P.L., Atkinson J., Skill M.J., Heal D.J. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol. Bull. 32:1996;123-128.
21. Olney J.W., Farber N.B. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J. Clin. Psychiatry. 55:1994;43-46.
22. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
23. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
24. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518.
25. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33:1999;523-533.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. 1998;Academic Press, San Diego, CA.
27. Petit M., Raniwalla J., Tweed J., Leutenegger E., Dollfus S., Kelly F. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol. Bull. 32:1996;81-87.
28. Puech A.J., Martin P. Classification of neuroleptics - zotepine. Pharmacopsychiatry. 20:1987;1-3.
29. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68:2000;29-39.
30. Rowley H.L., Needham P.L., Kilpatrick I.C., Heal D.J. A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo. Naunyn Schmiedeberg's Arch. Pharmacol. 361:2000;187-192.
31. Sharp F.R., Jasper P., Hall J., Noble L., Sagar S.M. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann. Neurol. 30:1991;801-809.
32. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12:1998;21-36.
33. Weizman R., Weizman A. Use of atypical antipsychotics in mood disorders. Curr. Opin. Investig. Drugs. 2:2001;940-945.